Objectives: Biotin is an essential cofactor for carbohydrate and lipid metabolism found in common foods. Supplementation with megadoses (5-10 mg/day) is widespread as it marketed as a beauty product. While not toxic, recent reports indicate that high levels of biotin in patient samples may interfere with diagnostic immunoassay (IA) using biotinylated antibodies, causing falsely low and falsely high results in competitive and noncompetitive IAs, respectively. Accordingly, the manufacturer of one such IA, Roche Diagnostics (Indianapolis, IN), recommends in the product insert not collecting samples from patients receiving high doses of biotin (>5 mg/day) until at least eight hours following the last administration. Here, we investigated the effect of over-the-counter (OTC) biotin when IAs are measured within hours of intake.
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Methods: Volunteers (n = 3) took biotin (10 mg) with food, and had samples collected at baseline, and 1 and 3 hrs post-intake. We measured eight analytes (TSH, FT4, T3, anti-TPO, CK-MB, cortisol, DHEAS, and folate), with claimed threshold for biotin tolerance of <30 ng/mL on the cobas e immunoassay analyzer (Roche Diagnostics). Biotin interference was defined as >10% change in results postingestion, and clinical significance as concentrations outside of the assay's reference interval. Results: Biotin interference was seen in six IAs in at least one individual, with falsely high results in the competitive IAs (FT4, T3, anti-TPO) and falsely low results in the noncompetitive IAs (TSH, DHEAS, cortisol). The interferences were clinically significant in three IAs (anti-TPO, T3, TSH) for two individuals in the 1 hr postintake sample. The biotin effects varied across individuals. Conclusions: Our data show that the interference of OTC biotin in IAs exhibits interindividual variability. Therefore, more studies are needed to understand the effect of biotin supplementation and individual pharmacokinetics. Providers must be aware of these effects and patients must cease biotin supplementation prior to sample collection.
